INTRODUCTION: Understanding the effects of microgravity on bone is essential, since humans are now considering long-distance spaceflight missions. It is well known that bone mineral density (BMD) decreases during long-duration spaceflight. While the risk of fracture in a microgravity
environment is believed to be low, the potential risk for fracture increases upon re-entering a gravity environment. The objective of this study was to determine skeletal regions of high-risk for fracture after long-duration spaceflight and identify management protocols for those fractures.METHODS:
A literature search was conducted on current fracture risk predictive models and suggestions for treatment.RESULTS: Exercise with the Advanced Resistance Exercise Device (ARED), T2 treadmill, and cycle ergometer with vibration isolation and stabilization (CEVIS) on the International
Space Station (ISS) is part of a fundamental long-duration spaceflight strategy to mitigate BMD loss. Additionally, studies have shown that bisphosphonates have an additive effect for preventing bone loss. However, if a fracture were to occur, treatments that improve bone healing in space
(in addition to standard management modalities such as splinting) include the use of low-intensity pulsed ultrasound, electromagnetic field therapy, and intermittent subcutaneous injections of parathyroid hormone. In the event of a complicated fracture, surgical intervention with a universal
external fixation device could be a viable option for management.CONCLUSION: In conclusion, the best strategy for mitigating musculoskeletal injuries for deep-space missions will be a combination of BMD loss reduction coupled with improvements in management protocols for potential
fractures.Swaffield TP, Neviaser AS, Lehnhardt K. Fracture risk in spaceflight and potential treatment options. Aerosp Med Hum Perform. 2018; 89(12):1060–1067.
Pharmaceuticals selected for exploration space missions must remain stable and effective throughout mission timeframes. Although there have been six spaceflight drug stability studies, there has not been a comprehensive analytical analysis of these data. We sought to use these studies to quantify the rate of spaceflight drug degradation and the time-dependent probability of drug failure resulting from the loss of active pharmaceutical ingredient (API). Additionally, existing spaceflight drug stability studies were reviewed to identify research gaps to be addressed prior to exploration missions. Data were extracted from the six spaceflight studies to quantify API loss for 36 drug products with long-duration exposure to spaceflight. Medications stored for up to 2.4 years in low Earth orbit (LEO) exhibit a small increase in the rate of API loss with a corresponding increase in risk of product failure. Overall, the potency for all spaceflight-exposed medications remains within 10% of terrestrial lot-matched control with a ~1.5 increase in degradation rate. All existing studies of spaceflight drug stability have focused primarily on repackaged solid oral medications, which is important because non-protective repackaging is a well-established factor contributing to loss of drug potency. The factor most detrimental to drug stability appears to be nonprotective drug repackaging, based on premature failure of drug products in the terrestrial control group. The result of this study supports a critical need to evaluate the effects of current repackaging processes on drug shelf life, and to develop and validate suitable protective repackaging strategies that help assure the stability of medications throughout the full duration of exploration space missions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.